Education
About Us
Working with TipRanks
Follow Us
Myriad Genetics (MYGN)
NASDAQ:MYGN
MYGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.36 - $29.30
Previous CloseN/A
Volume154.82K
Average Volume (3M)1.19M
Market Cap
$914.00M
Enterprise Value$2.53B
Total Cash (Recent Filing)$90.60M
Total Debt (Recent Filing)$273.30M
Price to Earnings (P/E)―
Beta1.68
Next Earnings
May 01, 2025EPS Estimate
-0.06Last Dividend Ex-Date
Jun 15, 2009Dividend YieldN/A
Share Statistics
EPS (TTM)-1.40
Shares Outstanding91,309,070
10 Day Avg. Volume1,058,621
30 Day Avg. Volume1,191,315
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.09
Price to Cash Flow (P/CF)34.60
P/FCF Ratio326.40
Enterprise Value/Market Cap2.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.90
Enterprise Value/Ebitda-51.27
Forecast
1Y Price Target
$15.59Price Target Upside60.23% Upside
Rating ConsensusHold
Number of Analyst Covering12
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceHereditary Cancer revenue grew by 6% year-over-year, with MyRisk revenue increasing by 8%.
Leadership And StrategyNew CEO Sam Raha has a chance to reset the business, make strategic decisions and provide reasonable expectations to match.
Partnership And InnovationA partnership with PATHOMIQ has been launched to advance AI-powered testing solutions, which is expected to accelerate the timeline for gaining Level 1 evidence for Prolaris.
Bears Say
Market ChallengesVolume growth was slower than expected due to a slowdown in the unaffected hereditary cancer business and delays in EMR workflow conversions.
Reimbursement And PricingGeneSight volumes continue to grow, but average selling price (ASP) is set to drop, with a 20%+ headwind from the UNH decision.
Revenue GuidanceRevenue guidance for the first quarter is below expectations, factoring in significant headwinds.
---
Ownership Overview
3.96% Insiders
24.81% Mutual Funds
21.94% Other Institutional Investors
20.11% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MYGN FAQ
What was Myriad Genetics’s price range in the past 12 months?
Myriad Genetics lowest stock price was $9.36 and its highest was $29.30 in the past 12 months.
What is Myriad Genetics’s market cap?
Myriad Genetics’s market cap is $914.00M.
When is Myriad Genetics’s upcoming earnings report date?
Myriad Genetics’s upcoming earnings report date is May 01, 2025 which is in 36 days.
How were Myriad Genetics’s earnings last quarter?
Myriad Genetics released its earnings results on Feb 24, 2025. The company reported $0.03 earnings per share for the quarter, the consensus estimate of $0.03 by $0.
Is Myriad Genetics overvalued?
According to Wall Street analysts Myriad Genetics’s price is currently Undervalued.
Does Myriad Genetics pay dividends?
Myriad Genetics pays a Notavailable dividend of $1.75 which represents an annual dividend yield of N/A. See more information on Myriad Genetics dividends here
What is Myriad Genetics’s EPS estimate?
Myriad Genetics’s EPS estimate is -0.06.
How many shares outstanding does Myriad Genetics have?
Myriad Genetics has 91,309,070 shares outstanding.
What happened to Myriad Genetics’s price movement after its last earnings report?
Myriad Genetics reported an EPS of $0.03 in its last earnings report, expectations of $0.03. Following the earnings report the stock price went down -14.804%.
Which hedge fund is a major shareholder of Myriad Genetics?
Currently, no hedge funds are holding shares in MYGN
---
Myriad Genetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$15.59 (60.23% Upside)
$15.59 (60.23% Upside)
Blogger Sentiment
Bullish
MYGN Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 2.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 8.7%
Last 30 Days ▼ 8.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.12%
12-Months-Change
Fundamentals
Return on Equity
-17.15%
Trailing 12-Months
Asset Growth
-17.56%
Trailing 12-Months
Company Description
Myriad Genetics
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
---
MYGN Company Deck
---
MYGN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Myriad Genetics reported a strong financial performance with significant revenue growth and strategic partnerships, despite facing challenges in GeneSight reimbursement and slower volume growth in certain segments.Read More>---
MYGN Stock 12 Month Forecast
Average Price Target
$15.59
▲(60.23% Upside)
Technical Analysis
Best Analysts Covering MYGN
1 Year
1 Year Success Rate
6/9 ratings generated profit
1 Year Average Return
+11.87%
reiterated a sell rating 30 days ago
Copying Rachel Vatnsdal's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +11.87% per trade.
---